Founded in 1899, MIT Technology Review is one of the world's oldest authoritative technology magazines. The TR35 Outstanding Young Innovative Persons Award is a fixed selection system established by the MIT Science Review to recognize young and innovative people. Each year, 35 academic and industrial elites under the age of 35 (TR35) are selected from around the world. The research results of the winners are leading the trend of technology development and changing the future of the world.
This year, MIT has selected 35, and the following 12 are innovative figures who are inextricably linked to the health care industry. Let us come to know them one by one, and their innovative inventions.
Kevin Esvelt, 34, Assistant Professor, Media Lab, Massachusetts Institute of Technology
According to the MIT Technology Review, Esvelt is a scientist who is engaged in the research and development of gene editing technology and warns and warns everyone about the potential harm of gene editing technology.
.jpg)
Esvelt holds a BS in Biochemistry from Harvey Mudd College, a leading engineering school in the United States, and a Ph.D. in Biochemistry from Harvard University. During his time at Harvard, he worked closely with researchers at George Church Labs. He also worked in the research of David Liu, co-founder of Editas Medicine, where he led the invention of the phage-assisted continuous evolution (PACE) technology. The research results were published in the top journal Nature (1). It is reported that the technology allows the organism to The evolution of molecules in the laboratory has increased 100 times.
As a gene-driven editor based on CRISPR gene editing (a technology system that uses genetic preferences to rapidly spread genes into populations, such as the use of gene-driven technologies to eliminate mosquitoes and thus eliminate infectious diseases such as malaria), the main researchers in the field of technology, Esvelt has his own thinking about gene-driven technology. He believes that any gene-driven technology that will spread globally cannot be used or even tested. Scientists must find a safe, genetically driven technology that can be controlled.
Due to Esvelt's important contribution in this field, in January 2016, MIT Media Lab hired him as an assistant professor to form the Sculpt Evolution research team. It is reported that he has developed a safe and controllable gene-driven technology. His contribution in this field has been highly appreciated by the FBI.
Evan Macosko, 34, Lecturer in Psychiatry, Massachusetts General Hospital
According to the MIT Science Review, Macosko made a major breakthrough in exploring how cells form tissues and organs.
.jpg)
People with a little bit of biological knowledge must have a question in their minds. People develop from a fertilized egg. The genetic material of each cell is the same. For some, it becomes a brain cell, and some become a foot. On the cells? What kind of difference is this kind of difference?
In fact, this difference is not reflected in the DNA level, but in the transcriptome RNA level. If we can understand how the differences between cells are formed, we can understand how many genes are controlled and how the disease occurs. The best way to understand this difference is to study a cell and a cell. Although there are now technologies for studying single cells, such as single cell sequencing technology. But the current technology is too expensive. If the research population is hundreds of millions of cells, the cost is no one can afford.
At the Harvard Medical School's geneticist Professor Steven McCarroll's research team, Macosko led a technology called "Drop-Seq", which was published in the top journal "Cell" in 2015 (2) .
With Drop-Seq technology, each cell requires only 6.5 cents for analysis, while the previous technology requires hundreds or thousands of dollars. Macosko said their next goal is to analyze 86 billion neurons and countless other cells in the human brain. He wanted to find the difference between all the cells in the human brain to identify the causes of brain diseases such as schizophrenia, autism, and Alzheimer's disease.
Kelly Gardner, 31, CEO of Zephyrus Biosciences
According to the MIT Technology Review, as a bioengineer, Gardner came up with the question of how to put the risks of biotech startups.
.jpg)
Zephyrus was founded in 2013 by Kelly Gardner in collaboration with Josh Molho and Amy E. Herr. The core technology of Zephyrus is the measurement of single-cell protein levels, and their measurement equipment Z1 is currently commercialized.
The reason for measuring single-cell protein levels is because the detection of single-cell proteins can help diagnose and treat cancer, so Gardner believes this is significant.
At the beginning of the business, Zephyrus only set the goal of measuring cellular proteins. Before developing the products, they visited more than 100 researchers to develop testing equipment to meet their needs. Due to the high risk of biotechnology innovation industrialization, investment institutions are reluctant to invest in start-up technology companies. So Gardner only made $1.8 million, and added seven employees to form Zephyrus. After more than two years of development, it was successfully acquired by Bio-Techne earlier this year.
Citrate Series,Potassium Citrate Anhydrous Food Additives,Eco Friendly Potassium Citrate,High Quality Potassium Citrate
LIANYUNGANGLONGTAIWEI FOOD INGREDIENTS CO.,LTD. , https://www.longtaiweifood.com